<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pityriasis rubra pilaris: Pathogenesis, clinical manifestations, and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pityriasis rubra pilaris: Pathogenesis, clinical manifestations, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pityriasis rubra pilaris: Pathogenesis, clinical manifestations, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Teri M Greiling, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristina Callis Duffin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H485978127"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pityriasis rubra pilaris (PRP) is a rare, cutaneous, inflammatory, papulosquamous disorder classically characterized by follicular, hyperkeratotic papules; waxy, yellow palmoplantar keratoderma; and erythroderma with islands of sparing  (<a class="graphic graphic_picture graphicRef86471 graphicRef86473 graphicRef86472 graphicRef86475 graphicRef86474 graphicRef131512 graphicRef131510 graphicRef131509 graphicRef131507 graphicRef131508 graphicRef86476" href="/d/graphic/86471.html" rel="external">picture 1A-K</a>). PRP may be acquired (most common) or familial, may have adult or childhood onset, and may have widespread or focal involvement. Other synonyms for PRP include Devergie's disease, lichen ruber pilaris, lichen acuminatus, and lichen ruber acuminatus.</p><p>The pathogenesis, clinical manifestations, and diagnosis of PRP will be reviewed here. The prognosis and management of PRP is discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/131425.html" rel="external">"Pityriasis rubra pilaris: Prognosis and management"</a>.)</p><p></p><p class="headingAnchor" id="H2614002999"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Clinical findings consistent with PRP were first recognized in the 1800s [<a href="#rid1">1-3</a>]. The incidence and prevalence of PRP are uncertain. A private PRP social media group associated with the nonprofit patient advocacy organization <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fprpalliance.com%2F&amp;token=kV9xQ9YNoTUTAoIzWjeuyp%2BrfEOyW15C0G1l1%2BHVr%2F6vALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=15283" target="_blank">PRP Alliance</a> has approximately 2000 active members worldwide:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age</strong> – PRP may occur at any age. The peak incidence has a bimodal distribution, with the first peak at age six to seven years [<a href="#rid4">4-6</a>]. The second peak occurs around the fifth or sixth decade of life [<a href="#rid7">7-10</a>]. Of note, the classical childhood-onset subtype of PRP usually develops in the late teenage years but may also be seen in the first few years of life [<a href="#rid5">5,8</a>]. (See <a class="local">'Clinical subtypes'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sex</strong> – PRP affects equal numbers of males and females in most case series [<a href="#rid4">4,6-12</a>]. However, other case series suggest a male predominance [<a href="#rid5">5,13-15</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Geographic distribution</strong> – PRP occurs worldwide. The largest published case series describe patients from the United States [<a href="#rid7">7,9,10,16</a>], Denmark [<a href="#rid14">14</a>], and Thailand [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">Estimates of incidence range widely, with studies suggesting incidences of 1 in 500 new dermatology patients in Kenya [<a href="#rid17">17</a>], 1 in 5000 new dermatology patients in Great Britain [<a href="#rid8">8</a>], and 1 in 50,000 new dermatology patients in India [<a href="#rid18">18</a>]. It is unclear whether observed differences in incidence relate to differences in risk for PRP in different populations, local differences in the diagnostic approach to PRP, or other factors. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Family history</strong> – Most cases of PRP are sporadic. There is an autosomal dominant inherited form that likely represents &lt;5 percent of patients [<a href="#rid6">6,12,16,19</a>]. (See <a class="local">'Pathogenesis'</a> below.)</p><p></p><p class="headingAnchor" id="H3949786151"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of PRP is not fully understood. The interleukin (IL) 23/Th17 axis may play an important role; this concept is supported by the response of PRP to therapies targeting IL-17 and IL-23. (See  <a class="medical medical_review" href="/d/html/131425.html" rel="external">"Pityriasis rubra pilaris: Prognosis and management", section on 'IL-17 inhibitors'</a> and  <a class="medical medical_review" href="/d/html/131425.html" rel="external">"Pityriasis rubra pilaris: Prognosis and management", section on 'IL-23 inhibitors'</a>.)</p><p>Familial PRP has been linked to autosomal dominant mutations in the <em>CARD14</em> gene. (See <a class="local">'CARD14, CCL20, and the IL-23/IL-17 axis'</a> below.)</p><p class="headingAnchor" id="H2955657877"><span class="h2"><i>CARD14</i>, CCL20, and the IL-23/IL-17 axis</span><span class="headingEndMark"> — </span>Insight into the cutaneous, inflammatory pathways involved in PRP has been gained through the study of genetic variants and transcriptomic analysis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of </strong><strong><em>CARD14</em></strong> – <em>CARD14</em> has been identified as a pathogenetic gene variation in families with autosomal dominant PRP [<a href="#rid20">20</a>] as well as in some individuals with sporadic PRP [<a href="#rid21">21</a>]<em>. CARD14</em> is part of the <em>PSORS2</em> gene locus and is also implicated in familial pustular psoriasis [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/89271.html" rel="external">"Pustular psoriasis: Pathogenesis, clinical manifestations, and diagnosis", section on 'Genetics'</a>.) </p><p></p><p class="bulletIndent1">Two mouse models recapitulating human <em>CARD14</em> genetic variants have helped elucidate the disease mechanism [<a href="#rid23">23,24</a>]. The mouse models exhibited cutaneous scale and erythema. The genetic variations led to constitutive activation of the <em>CARD14</em> gene product, CARMA2, with a downstream increase in the transcription factor nuclear factor kappa B (NF-kB) and resulting increase in the chemokine, CCL20, a potent activator of the Th17 pathway [<a href="#rid23">23</a>]. Injection of an anti-IL 23p19 antibody resulted in improvement in the skin disease [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1">Sporadic PRP is less understood, although there is emerging evidence that it may involve similar immune pathways to inherited PRP. An increase in CARD14, NF-kB, and CCL20 was found in cutaneous biopsies of patients with PRP who lacked germline <em>CARD14</em> mutations [<a href="#rid25">25-27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other insights</strong> – Other studies suggest that heterogeneity in the pathogenesis of PRP may contribute to differences in responses to treatment. In a transcriptomic analysis study of 11 adults with PRP, normalization in expression of <em>CCL20</em>, <em>IL17C</em>, and <em>IL23A </em>occurred in patients who responded well to treatment with an IL-17A inhibitor, whereas patients who responded poorly had higher baseline and post-treatment levels of <em>CCL20</em> and <em>IL17C</em> expression [<a href="#rid27">27</a>]. Activation of innate signaling pathways has also been detected in patients with poor responses to IL-17A inhibition [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/131425.html" rel="external">"Pityriasis rubra pilaris: Prognosis and management", section on 'IL-17 inhibitors'</a>.)</p><p></p><p class="bulletIndent1">Overlap in the pathogenic mechanisms of psoriasis and PRP is also proposed. In a study that compared gene expression in PRP and psoriasis, all dysregulated genes found in PRP skin were also found in psoriasis skin, and no genes were unique to PRP [<a href="#rid29">29</a>].</p><p></p><p class="headingAnchor" id="H274759092"><span class="h2">Drug-induced pityriasis rubra pilaris</span><span class="headingEndMark"> — </span>Drug exposure has been linked to the development of PRP  (<a class="graphic graphic_table graphicRef131804" href="/d/graphic/131804.html" rel="external">table 1</a>). Tyrosine kinase inhibitors (TKIs) and phosphoinositide 3-kinase (PI3K) inhibitors are the most often reported associated drugs  (<a class="graphic graphic_table graphicRef131804" href="/d/graphic/131804.html" rel="external">table 1</a>). </p><p>Based upon a systematic review that included reports of 25 patients with drug-associated PRP, the time period between drug initiation and PRP onset may range from three days to five months [<a href="#rid30">30</a>]. Proposed hypotheses for the mechanism of drug-induced PRP include drug-induced changes in regulatory immune surveillance, epidermal growth, and proinflammatory cytokine production, as well as effects related to drug exposure in the setting of underlying immunologic disorders [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H3377101839"><span class="h2">Other theories</span><span class="headingEndMark"> — </span>PRP was initially thought to be a disorder of <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> deficiency, but this association was subsequently dismissed. Early reports also linked PRP with neuromuscular disorders. This presentation was later recharacterized as Wong-type dermatomyositis, which presents with both PRP-like and dermatomyositis-like, cutaneous eruptions with or without myositis [<a href="#rid31">31</a>]. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>No human leukocyte antigen (HLA) association has been found in PRP [<a href="#rid19">19</a>]. Infectious or environmental triggers of PRP have been proposed but have not been definitively linked to PRP.</p><p class="headingAnchor" id="H3581146392"><span class="h1">CLINICAL SUBTYPES</span><span class="headingEndMark"> — </span>Multiple classification schemata for PRP have been proposed  (<a class="graphic graphic_table graphicRef131805" href="/d/graphic/131805.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Griffiths' classification</strong> – The most commonly cited classification schema for PRP is the Griffiths' classification, which consisted of five subtypes of PRP prior to the later addition of HIV-associated PRP [<a href="#rid8">8,32</a>]. However, it is important to note that these categories have not been validated to predict disease outcomes or treatment response:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Type I – Classical adult</p><p class="bulletIndent2"><span class="glyph">•</span>Type II – Atypical adult</p><p class="bulletIndent2"><span class="glyph">•</span>Type III – Classical juvenile</p><p class="bulletIndent2"><span class="glyph">•</span>Type IV – Circumscribed</p><p class="bulletIndent2"><span class="glyph">•</span>Type V – Atypical juvenile</p><p class="bulletIndent2"><span class="glyph">•</span>Type VI – HIV associated</p><p></p><p class="bulletIndent1">Classical adult PRP is considered the most common of these subtypes [<a href="#rid8">8,33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other classification schemata</strong> – Additional classification schemata include classification based upon PRP that is familial or acquired, childhood or adult onset, and typical or atypical in presentation [<a href="#rid16">16</a>]; classification by the body surface areas involved [<a href="#rid6">6</a>]; and classification of childhood-onset PRP by the duration of disease  (<a class="graphic graphic_table graphicRef131805" href="/d/graphic/131805.html" rel="external">table 2</a>) [<a href="#rid12">12</a>].</p><p></p><p class="headingAnchor" id="H3750444729"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>PRP has a range of clinical presentations.</p><p class="headingAnchor" id="H2068296520"><span class="h2">Primary features</span><span class="headingEndMark"> — </span>Two primary features (follicular, hyperkeratotic papules and palmoplantar keratoderma) link the various clinical presentations of PRP.</p><p class="headingAnchor" id="H3397228124"><span class="h3">Follicular, hyperkeratotic papules</span><span class="headingEndMark"> — </span>Follicular, hyperkeratotic papules manifest as multiple small, approximately 1 to 2 mm diameter papules with a central, smooth or sharp, keratotic plug  (<a class="graphic graphic_picture graphicRef131505 graphicRef86472 graphicRef131522 graphicRef86475" href="/d/graphic/131505.html" rel="external">picture 1C-D, 1L-M</a>). A surrounding yellow-orange ring may be visible in individuals with lightly pigmented skin, or the color may be red-brown in individuals with more deeply pigmented skin [<a href="#rid34">34</a>]. Although follicular, hyperkeratotic papules on the dorsal fingers has been proposed to be pathognomonic for PRP, this finding is often absent  (<a class="graphic graphic_picture graphicRef131522" href="/d/graphic/131522.html" rel="external">picture 1M</a>).</p><p>The appearance of follicular, hyperkeratotic papules has been likened to the round, sharp, grid array on the surface of a nutmeg or fine cheese grater. The term "nutmeg-grater sign" has been used to refer to this finding. </p><p class="headingAnchor" id="H2094579110"><span class="h3">Palmoplantar keratoderma</span><span class="headingEndMark"> — </span>Palmoplantar hyperkeratosis often appears early in the course of PRP. The palms and soles become diffusely hyperkeratotic and waxy with a yellow to orange hue  (<a class="graphic graphic_picture graphicRef131507 graphicRef86474" href="/d/graphic/131507.html" rel="external">picture 1E, 1I</a>). Severe cases exhibit dramatic hyperkeratosis and multiple painful fissures, which may have a profound, negative effect on daily activities, such as ambulation  (<a class="graphic graphic_picture graphicRef131508" href="/d/graphic/131508.html" rel="external">picture 1J</a>) [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H635762063"><span class="h2">Specific subtypes</span><span class="headingEndMark"> — </span>Classical, circumscribed, atypical, and HIV-associated presentations of PRP have additional characteristic features.</p><p class="headingAnchor" id="H2711445882"><span class="h3">Classical pityriasis rubra pilaris</span><span class="headingEndMark"> — </span>In addition to follicular hyperkeratosis and palmoplantar keratoderma, classical PRP in adults presents with inflamed plaques, islands of sparing, pityriasiform scale, and erythroderma [<a href="#rid36">36</a>]. Skin involvement often progresses in a cephalocaudal direction. Ectropion, hair loss, and nail abnormalities may also occur.</p><p>Classical PRP in childhood (classic juvenile PRP) is similar to the classical adult presentation, but fewer children develop complete erythroderma and ectropion  (<a class="graphic graphic_picture graphicRef131514" href="/d/graphic/131514.html" rel="external">picture 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous findings</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Erythematous plaques and lichenification</strong> – Follicular papules coalesce into larger, often deeply erythematous plaques, resulting in a lichenified appearance with exaggerated furrowing of the skin  (<a class="graphic graphic_picture graphicRef131509" href="/d/graphic/131509.html" rel="external">picture 1H</a>) [<a href="#rid12">12</a>]. In patients with highly pigmented skin, erythema may be subtle, and plaques may become hyperpigmented. (See <a class="local">'Skin of color'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Islands of sparing</strong> – The term "islands of sparing" refers to areas of normal-looking skin in the midst of affected areas. Islands of sparing usually appear or expand during the resolution phase of the disease  (<a class="graphic graphic_picture graphicRef86471 graphicRef131510 graphicRef86473" href="/d/graphic/86471.html" rel="external">picture 1A-B, 1G</a>). The presence of islands of sparing strongly suggests PRP, but the finding may also occur in erythroderma from other causes [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pityriasiform scale</strong> – Scale in classical PRP is fine, powdery, and nonadherent and has been likened to the bran of wheat [<a href="#rid36">36</a>]. Scaling is most prominent on the face and scalp  (<a class="graphic graphic_picture graphicRef131511" href="/d/graphic/131511.html" rel="external">picture 3</a>) [<a href="#rid36">36</a>]. Because of the nonadherent nature, patients may report clouds of dust falling from their skin despite having minimal scale visible on the surface of the skin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Erythroderma</strong> – Erythroderma is generally defined by the presence of erythema involving more than 90 percent of the body surface area. Erythema may be subtle in patients with highly pigmented skin. Erythroderma typically develops rapidly over approximately one month [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/d/html/13659.html" rel="external">"Erythroderma in adults", section on 'Cutaneous signs and symptoms'</a>.)</p><p></p><p class="bulletIndent2">Erythroderma is generally accompanied by heat and cold intolerance, edema of the legs (and sometimes the arms), and tachycardia. The skin is typically warm to touch. In addition, many patients with PRP report anhidrosis (loss of the ability to sweat) [<a href="#rid38">38,39</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cephalocaudal progression</strong> – Cephalocaudal progression of skin involvement is common in classical PRP  (<a class="graphic graphic_picture graphicRef131512 graphicRef86476" href="/d/graphic/131512.html" rel="external">picture 1F, 1K</a>). Erythema, follicular papules, and powdery, nonadherent scale often first appear on the scalp, followed by the face, chest, and upper back, and may progress in a cephalocaudal distribution until the patient becomes erythrodermic.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pruritus</strong> – Pruritus can be severe and is often disruptive to sleep [<a href="#rid35">35</a>]. Patients also frequently describe a stinging or burning sensation in the skin. Cutaneous dysesthesia often results in difficulty wearing clothing [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Photosensitivity</strong> – PRP exacerbation by ultraviolet light is common [<a href="#rid40">40-47</a>], although a smaller subset of patients improve with phototherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other findings</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ectropion</strong> – Prolonged facial involvement can result in ectropion and resulting eye pain, blurry vision, eye dryness, and epiphora [<a href="#rid36">36</a>]. Rarely, ectropion is severe and may lead to keratitis [<a href="#rid48">48,49</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nail abnormalities</strong> – Nail abnormalities can include terminal and subungual hyperkeratosis, splinter hemorrhages, and longitudinal ridging  (<a class="graphic graphic_picture graphicRef131513 graphicRef87823" href="/d/graphic/131513.html" rel="external">picture 4A-B</a>). Psoriasiform pits in the nail plate are an occasional finding, but the onycholysis and salmon patches commonly present in psoriasis are absent [<a href="#rid36">36</a>]. Nails may become thick, powdery, and may shed completely (onychomadesis) [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hair loss</strong> – Diffuse, nonscarring hair loss is common in classical PRP. However, complete alopecia does not occur, and hair loss is generally reversible after disease treatment or resolution [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Arthralgias</strong> – Generalized, noninflammatory arthralgias are commonly reported by patients with PRP, although true inflammatory arthritis is rare [<a href="#rid38">38,39</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ear canal blockage</strong> – Hyperkeratosis in the external auditory canals may lead to muffled hearing and require manual removal by a medical provider [<a href="#rid39">39</a>].</p><p></p><p class="headingAnchor" id="H1478491150"><span class="h3">Circumscribed pityriasis rubra pilaris</span><span class="headingEndMark"> — </span>Circumscribed PRP is the most common presentation of PRP in prepubertal children [<a href="#rid4">4,5</a>]. This subtype may also occur in adults.</p><p>Characteristic features of circumscribed PRP include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Circumscribed plaques</strong> – Well-demarcated plaques studded with follicular plugs develop over the extensor knees and elbows  (<a class="graphic graphic_picture graphicRef131515" href="/d/graphic/131515.html" rel="external">picture 5</a>). Other sites of involvement of follicular papules and plaques may include the dorsal hands, dorsal feet, and buttocks. Patients may also develop subtle, perioral and periorbital papules and plaques.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Palmoplantar keratoderma</strong> – Most patients also have palmoplantar keratoderma. Plantar involvement often extends over the Achilles tendon. (See <a class="local">'Palmoplantar keratoderma'</a> above.)</p><p></p><p>In addition, the scalp may contain large, adherent scales, and nails are also occasionally involved. Rarely, circumscribed PRP progresses to more classical, widespread PRP. (See <a class="local">'Classical pityriasis rubra pilaris'</a> above.)</p><p class="headingAnchor" id="H530304620"><span class="h3">Atypical adult-onset pityriasis rubra pilaris</span><span class="headingEndMark"> — </span>Atypical adult-onset PRP is rare.</p><p>Characteristic clinical features include [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Coarse, lamellated scale on the palms and soles  (<a class="graphic graphic_picture graphicRef131516" href="/d/graphic/131516.html" rel="external">picture 6</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Ichthyosis-like (larger, plate-like) scale on the legs</p><p class="bulletIndent1"><span class="glyph">●</span>Eczematous, ill-defined, erythematous patches </p><p class="bulletIndent1"><span class="glyph">●</span>Sparseness of scalp hair</p><p></p><p>In addition, some areas of follicular hyperkeratosis should be present. </p><p>The disease course is prolonged, typically lasting two decades or more [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H2091493834"><span class="h3">Atypical childhood-onset pityriasis rubra pilaris</span><span class="headingEndMark"> — </span>Atypical childhood-onset PRP (atypical juvenile PRP) is rare, usually develops in early childhood, and is often familial. </p><p>Typical clinical features may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Prominent facial involvement with well-demarcated, erythematous plaques on the cheeks and chin, sparing the infralabial region</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Follicular, hyperkeratotic papules with minimal, but persistent, erythema </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Erythematous, thin plaques with ichthyosiform or psoriasiform scale on the trunk and extremities </p><p></p><p>Occasionally, atypical childhood-onset of PRP is accompanied by scleroderma-like changes of the hands [<a href="#rid8">8</a>]. The course is typically chronic.</p><p>Of note, most patients considered to have atypical childhood-onset PRP would likely be better characterized as having either <em>CARD14</em>-associated papulosquamous eruption (CAPE) or a type of congenital ichthyosis. Genetic testing can be useful in this setting. (See <a class="local">'CARD14-associated papulosquamous eruption'</a> below and  <a class="medical medical_review" href="/d/html/15465.html" rel="external">"Overview and classification of the inherited ichthyoses", section on 'Diagnostic approach'</a>.)</p><p class="headingAnchor" id="H2699265895"><span class="h3">HIV-associated pityriasis rubra pilaris</span><span class="headingEndMark"> — </span>HIV-associated PRP is a rare subtype of PRP that can occur in the setting of either low or normal CD4 T cell counts. An association between HIV and PRP was first proposed in 1991 [<a href="#rid51">51</a>].</p><p>Patients with HIV-associated PRP present with cutaneous findings of classical PRP. There are reports of a tetrad of HIV-associated, follicular syndrome that includes PRP, acne conglobata, hidradenitis suppurativa, and lichen spinulosus [<a href="#rid52">52,53</a>].</p><p class="headingAnchor" id="H271214048"><span class="h1"><i>CARD14</i>-ASSOCIATED PAPULOSQUAMOUS ERUPTION</span><span class="headingEndMark"> — </span><em>CARD14</em> gene variations have been implicated in familial cases of PRP [<a href="#rid20">20</a>]. <em>CARD14</em>-associated papulosquamous eruption (CAPE) is a proposed term to describe the presence of PRP-like or psoriasis-like features in patients with <em>CARD14 </em>variations.</p><p>A study that identified 15 kindreds with <em>CARD14</em> gene variations among patients referred for participation in a genetic study of inherited disorders of keratinization led to the proposal of CAPE [<a href="#rid54">54</a>]. Early disease onset was common, with 13 of the 15 index patients with onset of disease at or before the age of one year. Physical findings included cutaneous findings that were primarily PRP like, primarily psoriasis like, or exhibited features of both conditions. Classical PRP findings detected included palmoplantar keratoderma (12 out of 15 patients), typical follicular papules (6 out of 15 patients), and islands of sparing (5 out of 15 patients). Fourteen out of 15 patients had prominent facial involvement, and two patients had scleroderma-like changes of the hands. Three of the 15 patients had arthritis.</p><p>CAPE shows similar histopathologic features as classical PRP [<a href="#rid54">54</a>], although acantholysis has not been described [<a href="#rid55">55</a>]. (See <a class="local">'Histopathology'</a> below.)</p><p class="headingAnchor" id="H2654005649"><span class="h1">PSYCHOSOCIAL IMPACT</span><span class="headingEndMark"> — </span>PRP is associated with a severe, negative impact on quality of life. A survey study that compared Skindex-29 quality-of-life scores from 85 patients in a PRP support group with existing data from other skin conditions found patients with PRP had worse quality of life than patients with all other dermatologic conditions included in the analysis except for epidermolysis bullosa [<a href="#rid47">47</a>]. Palmoplantar keratoderma was the largest factor that interfered with daily activities due to difficulty using the hands for fine motor tasks and feet for ambulating [<a href="#rid39">39,47</a>].</p><p>Moreover, reports of PRP-related depression, anxiety, and suicidal ideation were common in patient surveys [<a href="#rid9">9,35,39</a>]. Focus groups and surveys of participants with PRP also identified feelings of embarrassment, loss of self-worth, loneliness from having a rare disease, loneliness from not participating in social activities, demoralization by ineffective treatments, and uncertainty about diagnosis and prognosis [<a href="#rid39">39</a>]. The physical and mental impacts of PRP led to many patients feeling housebound and being unable to perform their usual work or home duties. (See  <a class="medical medical_review" href="/d/html/131425.html" rel="external">"Pityriasis rubra pilaris: Prognosis and management", section on 'Patient support'</a>.)</p><p class="headingAnchor" id="H970261800"><span class="h1">COMPLICATIONS</span><span class="headingEndMark"> — </span>Secondary bacterial infections are uncommon in PRP; however, secondary herpetic infections (Kaposi's varicelliform eruption) have been reported [<a href="#rid56">56-58</a>].</p><p class="headingAnchor" id="H3180761086"><span class="h1">HISTOPATHOLOGY</span><span class="headingEndMark"> — </span>There is no single histopathologic feature or known immunocytochemical marker that is diagnostic of PRP. A constellation of features supports the diagnosis and helps differentiate PRP from similar cutaneous diseases, such as psoriasis:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common features</strong> – Histopathologic features commonly found in established lesions of PRP include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Alternating orthokeratosis and parakeratosis</strong> – Stratum corneum with orthokeratosis and parakeratosis alternating in both vertical and horizontal directions, comparable to a checkerboard [<a href="#rid59">59</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Keratotic, follicular plugging</strong> – Keratotic, follicular plugging with perifollicular parakeratosis [<a href="#rid19">19</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Psoriasiform hyperplasia</strong> – Thickening of the epidermis with broad, short, irregular elongation of the rete ridges, known as psoriasiform hyperplasia, with normal or thickened suprapapillary plates (in contrast to psoriasis, which is associated with thinning of the suprapapillary plates) [<a href="#rid60">60,61</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Normal or thickened granular layer</strong> – Normal or thickened granular cell layer under areas of parakeratosis (in contrast to other inflammatory diseases that have a diminished or absent granular cell layer under areas of parakeratosis) [<a href="#rid61">61</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Mitotic figures</strong> – Mitotic figures above the basilar layer of the epidermis, although fewer than may be found in psoriasis [<a href="#rid60">60,61</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Acantholysis</strong> – Focal areas of acantholysis present in around one-quarter of PRP biopsies [<a href="#rid62">62</a>], with occasional widespread acantholysis mimicking pemphigus vulgaris [<a href="#rid63">63-65</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lymphocytic, inflammatory infiltrate</strong> – Dermis with sparse, perivascular, inflammatory infiltrate composed primarily of lymphocytes [<a href="#rid60">60,61</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Occasional features</strong> – Occasional histologic features include spongiosis; a brisk, lichenoid infiltrate with eosinophils [<a href="#rid10">10</a>]; scattered plasma cells; and dilated, superficial blood vessels (although not tortuous, as would be seen in psoriasis). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Features suggestive of other disorders</strong> – Interface dermatitis should be absent; the presence of interface dermatitis would be suggestive of Wong-type dermatomyositis. Intraepidermal lymphocytes should be minimal; the presence of intraepidermal lymphocytes would raise concern for cutaneous T cell lymphoma. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of disease stage</strong> – Early, evolving lesions of PRP are more likely to show a normal, basket-weave stratum corneum [<a href="#rid60">60</a>]. Late or partially resolved biopsies of PRP show a normal, basket-weave or compact, orthokeratotic stratum corneum with less psoriasiform hyperplasia [<a href="#rid60">60</a>].</p><p></p><p class="headingAnchor" id="H1870787634"><span class="h1">ASSOCIATED DISORDERS</span><span class="headingEndMark"> — </span>There are multiple case reports of PRP occurring in patients with concurrent medical conditions and malignancies, although whether these are stochastic events or related by disease mechanism is uncertain.</p><p>Inflammatory arthritis has also been associated with PRP in case reports [<a href="#rid66">66-74</a>]. Rarely, PRP has been temporally associated with eruptive seborrheic keratosis [<a href="#rid75">75-77</a>], immunologic abnormalities [<a href="#rid78">78-80</a>], autoimmune disorders [<a href="#rid5">5,81-85</a>], endocrine disorders [<a href="#rid12">12,86-89</a>], and Down syndrome [<a href="#rid90">90-92</a>].</p><p>PRP is not generally thought to be a paraneoplastic condition. Multiple malignancies have been suggested to be associated with PRP, but each is supported by isolated case reports. These include adenocarcinoma [<a href="#rid93">93-95</a>], bronchogenic carcinoma [<a href="#rid96">96</a>], cholangiocarcinoma [<a href="#rid97">97</a>], hepatocellular carcinoma [<a href="#rid98">98</a>], leukemia [<a href="#rid99">99</a>], meningioma [<a href="#rid100">100</a>], monoclonal gammopathy [<a href="#rid93">93</a>], melanoma [<a href="#rid101">101,102</a>], myelodysplastic syndrome [<a href="#rid103">103</a>], papillary renal cell carcinoma [<a href="#rid104">104</a>], and squamous cell carcinoma [<a href="#rid105">105,106</a>].</p><p class="headingAnchor" id="H2355063572"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of PRP is based on the recognition of consistent clinical and histopathologic features (see <a class="local">'Clinical features'</a> above and <a class="local">'Histopathology'</a> above). There are no validated diagnostic criteria for PRP.</p><p>Caution is indicated when diagnosing atypical adult-onset or atypical childhood-onset PRP. In the author's experience, adults with idiopathic erythroderma are sometimes labeled with atypical PRP despite lack of supporting clinical evidence of PRP. In addition, many patients considered to have childhood-onset PRP may be better classified as having <em>CARD14</em>-associated papulosquamous eruption (CAPE) or a form of congenital ichthyosis. (See <a class="local">'Differential diagnosis'</a> below and <a class="local">'Atypical childhood-onset pityriasis rubra pilaris'</a> above and <a class="local">'Genetic testing'</a> below.)</p><p class="headingAnchor" id="H755867653"><span class="h2">Patient history</span><span class="headingEndMark"> — </span>The patient history should include discussion of the age of onset, progression of skin involvement, and symptoms. A medication history should be obtained to explore the possibility of drug-induced PRP. Obtaining a family history can be helpful for identifying patients who may have CAPE or inherited PRP. (See <a class="local">'Genetic testing'</a> below and <a class="local">'CARD14-associated papulosquamous eruption'</a> above.)</p><p>A description of the progression of skin involvement can be particularly helpful for patients with classical PRP; once PRP has become erythrodermic, it can be difficult to discern PRP from other types of erythroderma. Patients with classical PRP typically first describe the initial development of scale and erythema of the scalp, with spread to the face, chest, and upper back, followed by involvement of the remainder of the body. Waxy keratoderma of the palms and soles starts early in the disease course and may become thicker with fissuring as progression occurs. (See <a class="local">'Classical pityriasis rubra pilaris'</a> above.) </p><p class="headingAnchor" id="H1366955444"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>A complete skin examination should be performed to detect common signs of PRP (eg, follicular, hyperkeratotic papules; palmoplantar keratoderma; plaques; pityriasiform scale; islands of sparing; or erythroderma). (See <a class="local">'Clinical features'</a> above.)</p><p>Dermoscopic examination may be useful in differentiating PRP from similar inflammatory disorders, although this has not been well validated. Examples of reported dermoscopic findings include white scale; dotted vessels with orange, structureless areas; and reticular vessels in the islands of spared skin [<a href="#rid107">107-109</a>]. This contrasts with the more regular pattern of dotted and glomerular vessels observed in erythrodermic psoriasis [<a href="#rid108">108,109</a>]. Areas of follicular hyperkeratosis, as well as the scalp, may show a central hair with a follicular plug surrounded by an orange/yellow halo [<a href="#rid110">110-114</a>].</p><p class="headingAnchor" id="H2011096130"><span class="h3">Skin of color</span><span class="headingEndMark"> — </span>In patients with highly pigmented skin, follicular papules and erythema have a red-brown color, rather than a pink-orange hue [<a href="#rid34">34</a>]. Postinflammatory hyperpigmentation may also occur, causing papules or plaques to appear darker than surrounding skin. Careful attention to other features of PRP, such as the morphology and distribution of lesions and the progression of disease (eg, cephalocaudal progression in classical PRP), and histopathologic examination can aid with diagnosis.</p><p class="headingAnchor" id="H4027422577"><span class="h2">Skin biopsy</span><span class="headingEndMark"> — </span>Skin biopsies to identify consistent histopathologic findings are an important diagnostic tool for PRP. (See <a class="local">'Histopathology'</a> above.)</p><p>The skin biopsy specimen should be taken from an involved area of the skin, ideally in a location where hyperkeratotic, follicular, scaly papules are observed. Typically, two 4 mm punch biopsies are preferred, given the sometimes nonspecific histopathologic changes that may be found. A shave biopsy through the mid-dermis may also be adequate.</p><p class="headingAnchor" id="H1198207500"><span class="h1">ADDITIONAL TESTS</span></p><p class="headingAnchor" id="H866413495"><span class="h2">HIV testing</span><span class="headingEndMark"> — </span>Because of the possibility of HIV-associated PRP, we screen adolescent and adult patients with PRP for HIV infection. (See  <a class="medical medical_review" href="/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection"</a>.)</p><p class="headingAnchor" id="H1105454408"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>We suggest genetic testing for <em>CARD14</em> gene variations for patients with PRP onset in the first year of life, children who have PRP symptoms that persist for longer than three years, or children with family members with known or suspected PRP or psoriasis. Of note, individuals with <em>CARD14</em>-associated papulosquamous eruption (CAPE) may have either classical or atypical features (see <a class="local">'CARD14-associated papulosquamous eruption'</a> above). The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.firstskinfoundation.org%2Fichthyosis-registry&amp;token=Ncn10HkhF6mbL4%2F3QZNMbuZP3IeVW5YnkFANpVKCeSEhoWExxqWKP6zqI8T44%2F7E6JNpDZ1nZxVuEf2hVEIxcQ%3D%3D&amp;TOPIC_ID=15283" target="_blank">Foundation for Ichthyosis and Related Skin Disorders</a> is a resource for genetic testing.</p><p class="headingAnchor" id="H2923820802"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Examples of disorders in the differential diagnosis of PRP include seborrheic dermatitis, erythrodermic psoriasis and other forms of erythroderma, chronic plaque psoriasis, Wong-type dermatomyositis, and erythema gyratum repens:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Seborrheic dermatitis</strong> – Early classical PRP may be mistaken for seborrheic dermatitis because of the cephalocaudal progression of PRP. Seborrheic dermatitis commonly presents with erythematous, scaly patches on the scalp and may also involve the eyebrows, nasolabial folds, and, less commonly, the central chest and intertriginous areas  (<a class="graphic graphic_picture graphicRef114636 graphicRef126095" href="/d/graphic/114636.html" rel="external">picture 7A-B</a>). The characteristic greasy scale, absence of follicular hyperkeratosis and palmoplantar keratoderma, and relatively stable distribution of seborrheic dermatitis distinguish this disorder from PRP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythrodermic psoriasis and other forms of erythroderma</strong> – Erythroderma in PRP can closely resemble erythroderma secondary to other causes. Psoriasis is one of the most common causes of erythroderma  (<a class="graphic graphic_picture graphicRef111553" href="/d/graphic/111553.html" rel="external">picture 8</a>). Examples of other causes include atopic dermatitis, drug reactions, and cutaneous T cell lymphoma (Sézary syndrome). Erythroderma may also be idiopathic. Palmoplantar keratoderma, pruritus, and lymphadenopathy are common in various forms of erythroderma. (See  <a class="medical medical_review" href="/d/html/13659.html" rel="external">"Erythroderma in adults"</a>.)</p><p></p><p class="bulletIndent1">The patient history, physical examination, and skin biopsy can be helpful for identifying erythrodermic psoriasis. Patients with erythrodermic psoriasis often have a history of psoriasis. Psoriasis also tends to have a more adherent scale than PRP, but this can be subtle. On histopathologic examination, the presence of keratotic, follicular plugging; a normal or increased granular cell layer; acantholysis; and the notable absence of neutrophils in the stratum corneum support a diagnosis of PRP [<a href="#rid61">61</a>]. Dermoscopy has also been proposed to help differentiate between erythrodermic PRP and psoriasis, with the presence of regular, dotted, and glomerular vessels observed in psoriasis versus less regular, dotted vessels within orange, structureless areas in PRP [<a href="#rid107">107-109</a>]. (See  <a class="medical medical_review" href="/d/html/110151.html" rel="external">"Erythrodermic psoriasis in adults"</a> and <a class="local">'Physical examination'</a> above.)</p><p></p><p class="bulletIndent1">As with other forms of erythroderma in the differential diagnosis, cutaneous T cell lymphoma should lack the follicular papules of PRP. However, the erythrodermic stage can be difficult to discern clinically from PRP, and there is a case report of Sézary syndrome initially presenting with follicular papules suspected to be PRP [<a href="#rid115">115</a>]. Blood flow cytometry or T cell clonality studies are important when cutaneous T cell lymphoma is suspected. (See  <a class="medical medical_review" href="/d/html/16193.html" rel="external">"Clinical presentation, pathologic features, and diagnosis of Sézary syndrome"</a>.)</p><p></p><p class="bulletIndent1">In our experience, idiopathic erythroderma is sometimes inappropriately diagnosed as atypical PRP despite the lack of histopathologic features suggestive of PRP. (See <a class="local">'Histopathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic plaque psoriasis</strong> – Chronic plaque psoriasis is characterized by well-demarcated, inflamed plaques with micaceous scale. Similar to circumscribed PRP, common locations for psoriasis are the extensor elbows, knees, scalp, palms, and soles  (<a class="graphic graphic_picture graphicRef54581 graphicRef87443" href="/d/graphic/54581.html" rel="external">picture 9A-B</a>). However, psoriatic plaques lack the follicular nature of PRP. A skin biopsy can be helpful for distinguishing plaque psoriasis and PRP [<a href="#rid61">61</a>]. (See <a class="local">'Histopathology'</a> above and  <a class="medical medical_review" href="/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Wong-type dermatomyositis</strong> – Wong-type dermatomyositis is a rare disorder that presents with clinical and histopathologic features of both PRP and dermatomyositis (eg, follicular, keratotic papules on the trunk and waxy, orange keratoderma of the soles similar to PRP and a heliotrope eruption on the eyelids with Gottron papules over the dorsal hands similar to dermatomyositis). Patients with Wong-type dermatomyositis may exhibit myositis or may be amyopathic. An additional skin biopsy taken from a cutaneous eruption suggestive of dermatomyositis, as well as a muscle examination and muscle enzymes, can be helpful for distinguishing Wong-type dermatomyositis from PRP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Erythema gyratum repens</strong> – Erythema gyratum repens is a rare, paraneoplastic, cutaneous eruption with unique and characteristic migratory, annular, and arcuate plaques resembling wood grain  (<a class="graphic graphic_picture graphicRef131520" href="/d/graphic/131520.html" rel="external">picture 10</a>). It may be accompanied by palmoplantar keratoderma. Erythema gyratum repens is most often associated with lung carcinoma. Resolving PRP can mimic erythema gyratum repens but lacks the migratory nature of erythema gyratum repens [<a href="#rid116">116-122</a>]. (See  <a class="medical medical_review" href="/d/html/7606.html" rel="external">"Cutaneous manifestations of internal malignancy", section on 'Erythema gyratum repens'</a>.)</p><p></p><p>Other mimickers of PRP may include hypereosinophilic syndrome, severe tinea versicolor [<a href="#rid123">123,124</a>], and PRP-like graft-versus-host disease [<a href="#rid125">125,126</a>].</p><p class="headingAnchor" id="H1699813841"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – Pityriasis rubra pilaris (PRP) is a rare, cutaneous, inflammatory, papulosquamous disorder that occurs in both adults and children. PRP can have a profound, negative impact on quality of life. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Psychosocial impact'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The pathogenesis of sporadic PRP is not fully understood. The interleukin (IL) 23/Th17 axis may play an important role.</p><p></p><p class="bulletIndent1">Most cases of PRP are sporadic, with familial PRP accounting for a small subset of cases. Familial PRP has been linked to mutations in the <em>CARD14</em> gene. Drug exposure may contribute to some cases of PRP  (<a class="graphic graphic_table graphicRef131804" href="/d/graphic/131804.html" rel="external">table 1</a>). (See <a class="local">'Epidemiology'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical subtypes</strong> – The most common classification scheme divides PRP into six subtypes  (<a class="graphic graphic_table graphicRef131805" href="/d/graphic/131805.html" rel="external">table 2</a>): </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Type I – Classical adult</p><p class="bulletIndent2"><span class="glyph">•</span>Type II – Atypical adult</p><p class="bulletIndent2"><span class="glyph">•</span>Type III – Classical juvenile</p><p class="bulletIndent2"><span class="glyph">•</span>Type IV – Circumscribed</p><p class="bulletIndent2"><span class="glyph">•</span>Type V – Atypical juvenile</p><p class="bulletIndent2"><span class="glyph">•</span>Type VI – HIV associated</p><p></p><p class="bulletIndent1">Classical adult PRP is the most common of these subtypes. (See <a class="local">'Clinical subtypes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The clinical presentation of PRP varies  (<a class="graphic graphic_picture graphicRef86471 graphicRef86473 graphicRef86472 graphicRef86475 graphicRef86474 graphicRef131512 graphicRef131510 graphicRef131509 graphicRef131507 graphicRef131508 graphicRef86476" href="/d/graphic/86471.html" rel="external">picture 1A-K</a>). Follicular, hyperkeratotic papules and palmoplantar hyperkeratosis are characteristic features.</p><p></p><p class="bulletIndent1">Patients with classical PRP may also exhibit plaques, pityriasiform scale, islands of sparing, cephalocaudal progression of skin involvement, and erythroderma. Other subtypes exhibit different features. Limited, focal skin involvement with plaques studded with follicular plugs is characteristic of circumscribed PRP, which is more common in children. Coarser scale may be present on the palms, soles, and legs in atypical PRP. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – A diagnosis of PRP can be made based upon the presence of consistent clinical and histopathologic findings. The patient history, physical examination, and skin biopsy are important for the evaluation and may be particularly helpful for distinguishing psoriasis and PRP. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of genetic testing</strong> – Genetic testing is appropriate for children with PRP onset before one year of age, children with PRP that does not remit within three years, or children with a family history of PRP or psoriasis. (See <a class="local">'Genetic testing'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Tarral C. Observation CXVIII. In: Traité Théorique et Pratique des Maladies de la Peau, 2nd ed, Rayer P (Ed), Bailliere, 1835. p.158.</li><li><a class="nounderline abstract_t">Devergie M. Pityriasis pilaris, maladie de peau non decrite par les dermatologists. Gazette Hebdomadaire de Med et de Chirung 1856; 3:197.</a></li><li><a class="nounderline abstract_t">Besnier E. Du pityriasis rubra pilaire. Ann Dermatol Syphiligr (Paris) 1889; 10:253.</a></li><li><a class="nounderline abstract_t">Yang CC, Shih IH, Lin WL, et al. Juvenile pityriasis rubra pilaris: report of 28 cases in Taiwan. J Am Acad Dermatol 2008; 59:943.</a></li><li><a class="nounderline abstract_t">Allison DS, El-Azhary RA, Calobrisi SD, Dicken CH. Pityriasis rubra pilaris in children. J Am Acad Dermatol 2002; 47:386.</a></li><li><a class="nounderline abstract_t">Piamphongsant T, Akaraphant R. Pityriasis rubra pilaris: a new proposed classification. Clin Exp Dermatol 1994; 19:134.</a></li><li><a class="nounderline abstract_t">KIERLAND RR, KULWIN MH. Pityriasis rubra pilaris; a clinical study. Arch Derm Syphilol 1950; 61:925.</a></li><li><a class="nounderline abstract_t">Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol 1980; 5:105.</a></li><li><a class="nounderline abstract_t">Ross NA, Chung HJ, Li Q, et al. Epidemiologic, Clinicopathologic, Diagnostic, and Management Challenges of Pityriasis Rubra Pilaris: A Case Series of 100 Patients. JAMA Dermatol 2016; 152:670.</a></li><li><a class="nounderline abstract_t">Ghatnekar S, Shah N, Min MS, et al. Clinical features and eosinophilia in pityriasis rubra pilaris: A multicenter cohort. J Am Acad Dermatol 2022; 86:907.</a></li><li><a class="nounderline abstract_t">Marrouche N, Kurban M, Kibbi AG, Abbas O. Pityriasis rubra pilaris: clinicopathological study of 32 cases from Lebanon. Int J Dermatol 2014; 53:434.</a></li><li><a class="nounderline abstract_t">Gelmetti C, Schiuma AA, Cerri D, Gianotti F. Pityriasis rubra pilaris in childhood: a long-term study of 29 cases. Pediatr Dermatol 1986; 3:446.</a></li><li><a class="nounderline abstract_t">Lim JT, Tham SN. Pityriasis rubra pilaris in Singapore. Clin Exp Dermatol 1991; 16:181.</a></li><li><a class="nounderline abstract_t">Sørensen KB, Thestrup-Pedersen K. Pityriasis rubra pilaris: a retrospective analysis of 43 patients. Acta Derm Venereol 1999; 79:405.</a></li><li><a class="nounderline abstract_t">Kromer C, Sabat R, Celis D, Mössner R. Systemic therapies of pityriasis rubra pilaris: a systematic review. J Dtsch Dermatol Ges 2019; 17:243.</a></li><li><a class="nounderline abstract_t">Davidson CL Jr, Winkelmann RK, Kierland RR. Pityriasis rubra pilaris. A follow-up study of 57 patients. Arch Dermatol 1969; 100:175.</a></li><li><a class="nounderline abstract_t">Verhagen AR, Koten JW, Chaddah VK, Patel RI. Skin diseases in Kenya. A clinical and histopathological study of 3,168 patients. Arch Dermatol 1968; 98:577.</a></li><li><a class="nounderline abstract_t">Sehgal VN, Jain MK, Mathur RP. Pityriasis rubra pilaris in Indians. Br J Dermatol 1989; 121:821.</a></li><li><a class="nounderline abstract_t">Niemi KM, Kousa M, Storgards K, Karvonen J. Pityriasis rubra pilaris. A clinico-pathological study with a special reference to autoradiography and histocompatibility antigens. Dermatologica 1976; 152:109.</a></li><li><a class="nounderline abstract_t">Fuchs-Telem D, Sarig O, van Steensel MA, et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet 2012; 91:163.</a></li><li><a class="nounderline abstract_t">Li Q, Jin Chung H, Ross N, et al. Analysis of CARD14 Polymorphisms in Pityriasis Rubra Pilaris: Activation of NF-κB. J Invest Dermatol 2015; 135:1905.</a></li><li><a class="nounderline abstract_t">Berki DM, Liu L, Choon SE, et al. Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris. J Invest Dermatol 2015; 135:2964.</a></li><li><a class="nounderline abstract_t">Wang M, Zhang S, Zheng G, et al. Gain-of-Function Mutation of Card14 Leads to Spontaneous Psoriasis-like Skin Inflammation through Enhanced Keratinocyte Response to IL-17A. Immunity 2018; 49:66.</a></li><li><a class="nounderline abstract_t">Mellett M, Meier B, Mohanan D, et al. CARD14 Gain-of-Function Mutation Alone Is Sufficient to Drive IL-23/IL-17-Mediated Psoriasiform Skin Inflammation In Vivo. J Invest Dermatol 2018; 138:2010.</a></li><li><a class="nounderline abstract_t">Eytan O, Qiaoli L, Nousbeck J, et al. Increased epidermal expression and absence of mutations in CARD14 in a series of patients with sporadic pityriasis rubra pilaris. Br J Dermatol 2014; 170:1196.</a></li><li><a class="nounderline abstract_t">Strunck JL, Cutler B, Rajpal B, et al. Pityriasis Rubra Pilaris Response to IL-17A Inhibition Is Associated with IL-17C and CCL20 Protein Levels. J Invest Dermatol 2022; 142:235.</a></li><li><a class="nounderline abstract_t">Haynes D, Reiter T, Velasco R, et al. Pityriasis Rubra Pilaris Transcriptomics Implicate T Helper 17 Signaling and Correlate with Response to Ixekizumab, with Distinct Gene Expression Profiles in Nonresponders. J Invest Dermatol 2023; 143:501.</a></li><li><a class="nounderline abstract_t">Boudreaux BW, Pincelli TP, Bhullar PK, et al. Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis. Br J Dermatol 2022; 187:650.</a></li><li><a class="nounderline abstract_t">Shao S, Chen J, Swindell WR, et al. Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris. JCI Insight 2021; 6.</a></li><li><a class="nounderline abstract_t">Mufti A, Lytvyn Y, Maliyar K, et al. Drugs associated with development of pityriasis rubra pilaris: A systematic review. J Am Acad Dermatol 2021; 84:1071.</a></li><li><a class="nounderline abstract_t">Wong KO. Systemic lupus erythematosus: a report of forty-five cases with unusual clinical and immunological features. Br J Dermatol 1969; 81:186.</a></li><li><a class="nounderline abstract_t">Miralles ES, Núñez M, De Las Heras ME, et al. Pityriasis rubra pilaris and human immunodeficiency virus infection. Br J Dermatol 1995; 133:990.</a></li><li><a class="nounderline abstract_t">Jacyk WK. Pityriasis rubra pilaris in black South Africans. Clin Exp Dermatol 1999; 24:160.</a></li><li><a class="nounderline abstract_t">Plante JG, Aleisa AI, Thiers BH. Pityriasis rubra pilaris in skin of color. Int J Womens Dermatol 2021; 7:207.</a></li><li><a class="nounderline abstract_t">Ji-Xu A, Lei DK, Worswick S, et al. Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris. Br J Dermatol 2022; 187:1024.</a></li><li><a class="nounderline abstract_t">Griffiths WA. Pityriasis rubra pilaris--an historical approach. 2. Clinical features. Clin Exp Dermatol 1976; 1:37.</a></li><li><a class="nounderline abstract_t">Gross DA, Landau JW, Newcomer VD. Pityriasis rubra pilaris. Report of a case and analysis of the literature. Arch Dermatol 1969; 99:710.</a></li><li><a class="nounderline abstract_t">Halper K, Wright B, Maloney NJ, et al. Characterizing Disease Features and Other Medical Diagnoses in Patients With Pityriasis Rubra Pilaris. JAMA Dermatol 2020; 156:1373.</a></li><li><a class="nounderline abstract_t">Velasco RC, Cutler B, McCue W, Greiling TM. The comprehensive impact of pityriasis rubra pilaris on physical symptoms, mental health, and activities of daily living: A mixed methods study. JEADV Clin Pract 2023; 2:184.</a></li><li><a class="nounderline abstract_t">Iredale HE, Meggitt SJ. Photosensitive pityriasis rubra pilaris. Clin Exp Dermatol 2006; 31:36.</a></li><li><a class="nounderline abstract_t">Evangelou G, Murdoch SR, Palamaras I, Rhodes LE. Photoaggravated pityriasis rubra pilaris. Photodermatol Photoimmunol Photomed 2005; 21:272.</a></li><li><a class="nounderline abstract_t">Kaskel P, Grundmann-Kollmann M, Schiller PI, et al. Bath-PUVA as a treatment for Pityriasis rubra pilaris provoked by ultraviolet B. Br J Dermatol 1999; 140:769.</a></li><li><a class="nounderline abstract_t">Yaniv R, Barzilai A, Trau H. Pityriasis rubra pilaris exacerbated by ultraviolet B phototherapy. Dermatology 1994; 189:313.</a></li><li><a class="nounderline abstract_t">Khoo L, Asawanonda P, Grevelink SA, Taylor CR. Narrow-band UVB-associated lesional blisters in pityriasis rubra pilaris. J Am Acad Dermatol 1999; 41:803.</a></li><li><a class="nounderline abstract_t">Męcińska-Jundziłł K, Białecka A, Adamska U, et al. Photosensitive pityriasis rubra pilaris. Postepy Dermatol Alergol 2016; 33:239.</a></li><li><a class="nounderline abstract_t">Marguery MC, Durand-Malgouyres C, Bayle-Lebey P, et al. Photosensitive and phototriggered pityriasis rubra pilaris. Photodermatol Photoimmunol Photomed 1994; 10:42.</a></li><li><a class="nounderline abstract_t">Eastham AB, Tkachenko EY, Femia AN, et al. Pityriasis rubra pilaris: A study evaluating patient quality of life in 2 populations. J Am Acad Dermatol 2019; 81:638.</a></li><li><a class="nounderline abstract_t">Kitzmann AS, Goins KM, Syed NA, Wagoner MD. Bilateral herpes simplex keratitis with unilateral secondary bacterial keratitis and corneal perforation in a patient with pityriasis rubra pilaris. Cornea 2008; 27:1212.</a></li><li><a class="nounderline abstract_t">Paranjothy B, Shunmugam M, MacKenzie J, Azuara-Blanco A. Peripheral ulcerative keratitis in pityriasis rubra pilaris. Eye (Lond) 2007; 21:1001.</a></li><li><a class="nounderline abstract_t">Sonnex TS, Dawber RP, Zachary CB, et al. The nails in adult type 1 pityriasis rubra pilaris. A comparison with Sézary syndrome and psoriasis. J Am Acad Dermatol 1986; 15:956.</a></li><li><a class="nounderline abstract_t">Blauvelt A, Nahass GT, Pardo RJ, Kerdel FA. Pityriasis rubra pilaris and HIV infection. J Am Acad Dermatol 1991; 24:703.</a></li><li><a class="nounderline abstract_t">Sánchez-Regaña M, Fuentes CG, Creus L, et al. Pityriasis rubra pilaris and HIV infection: a part of the spectrum of HIV-associated follicular syndrome. Br J Dermatol 1995; 133:818.</a></li><li><a class="nounderline abstract_t">Resnick SD, Murrell DF, Woosley JT. Pityriasis rubra pilaris, acne conglobata, and elongated follicular spines: an HIV-associated follicular syndrome? J Am Acad Dermatol 1993; 29:283.</a></li><li><a class="nounderline abstract_t">Craiglow BG, Boyden LM, Hu R, et al. CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris. J Am Acad Dermatol 2018; 79:487.</a></li><li><a class="nounderline abstract_t">Ring NG, Craiglow BG, Panse G, et al. Histopathologic findings characteristic of CARD14-associated papulosquamous eruption. J Cutan Pathol 2020; 47:425.</a></li><li><a class="nounderline abstract_t">Ng SK, Ang CB, Tham A. Kaposi's varicelliform eruption in a patient with pityriasis rubra pilaris. J Am Acad Dermatol 1992; 27:263.</a></li><li><a class="nounderline abstract_t">Erdag G, Lockman D, Tromberg J, et al. A case of pityriasis rubra pilaris with associated focal acantholytic dyskeratosis complicated by Kaposi's varicelliform eruption. J Cutan Pathol 2011; 38:919.</a></li><li><a class="nounderline abstract_t">Cavalié M, Giacchero D, Cardot-Leccia N, et al. Kaposi's varicelliform eruption in a patient with pityriasis rubra pilaris (pityriasis rubra pilaris herpeticum). J Eur Acad Dermatol Venereol 2013; 27:1585.</a></li><li class="breakAll">Ackermann AB. Histologic Diagnosis of Inflammatory Skin Diseases, Lea and Febiger, 1978.</li><li><a class="nounderline abstract_t">Soeprono FF. Histologic criteria for the diagnosis of pityriasis rubra pilaris. Am J Dermatopathol 1986; 8:277.</a></li><li><a class="nounderline abstract_t">Magro CM, Crowson AN. The clinical and histomorphological features of pityriasis rubra pilaris. A comparative analysis with psoriasis. J Cutan Pathol 1997; 24:416.</a></li><li><a class="nounderline abstract_t">Avitan-Hersh E, Bergman R. The Incidence of Acantholysis in Pityriasis Rubra Pilaris-Histopathological Study Using Multiple-Step Sections and Clinicopathologic Correlations. Am J Dermatopathol 2015; 37:755.</a></li><li><a class="nounderline abstract_t">Ko CJ, Milstone LM, Choi J, McNiff JM. Pityriasis rubra pilaris: the clinical context of acantholysis and other histologic features. Int J Dermatol 2011; 50:1480.</a></li><li><a class="nounderline abstract_t">Lilo MT, Yan S, Chapman MS, Linos K. Pityriasis Rubra Pilaris With Extensive Follicular Acantholysis Resembling Pemphigus Vulgaris: A Case Report. Am J Dermatopathol 2019; 41:37.</a></li><li><a class="nounderline abstract_t">Sebastian A, Koff AB, Goldberg LJ. PRP with subcorneal acantholysis: case report and review. J Cutan Pathol 2010; 37:99.</a></li><li><a class="nounderline abstract_t">Fiallo P, Tagliapietra AG, Santoro G. Arthropathic pityriasis rubra pilaris. Br J Dermatol 1996; 134:1154.</a></li><li><a class="nounderline abstract_t">Conaghan PG, Sommer S, McGonagle D, et al. The relationship between pityriasis rubra pilaris and inflammatory arthritis: case report and response of the arthritis to anti-tumor necrosis factor immunotherapy. Arthritis Rheum 1999; 42:1998.</a></li><li><a class="nounderline abstract_t">Behr FD, Bangert JL, Hansen RC. Atypical pityriasis rubra pilaris associated with arthropathy and osteoporosis: a case report with 15-year follow-up. Pediatr Dermatol 2002; 19:46.</a></li><li><a class="nounderline abstract_t">Nakafusa J, Misago N, Narisawa Y. Pityriasis rubra pilaris in association with polyarthritis. Dermatology 2002; 205:298.</a></li><li><a class="nounderline abstract_t">Chan H, Liu FT, Naguwa S. A review of pityriasis rubra pilaris and rheumatologic associations. Clin Dev Immunol 2004; 11:57.</a></li><li><a class="nounderline abstract_t">Liu PY, Prete PE. Arthritis associated with pityriasis rubra pilaris. BMJ Case Rep 2010; 2010.</a></li><li><a class="nounderline abstract_t">Aguilar AR, Gomez F, Balsa FT, et al. Pityriasis rubra pilaris with muscle and joint involvement. Dermatologica 1973; 146:361.</a></li><li><a class="nounderline abstract_t">Duke RA, Barrett MR, Salazar JE, et al. Acro-osteolysis secondary to pityriasis rubra pilaris. AJR Am J Roentgenol 1987; 149:1082.</a></li><li><a class="nounderline abstract_t">Lister RK, Perry JD, Cerio R. Pityriasis rubra pilaris and a seronegative polyarthritis. Br J Dermatol 1997; 137:318.</a></li><li><a class="nounderline abstract_t">Schwengle LE, Rampen FH. Eruptive seborrheic keratoses associated with erythrodermic pityriasis rubra pilaris. Possible role of retinoid therapy. Acta Derm Venereol 1988; 68:443.</a></li><li><a class="nounderline abstract_t">Gleeson CM, Chan I, Griffiths WA, Bunker CB. Eruptive seborrhoeic keratoses associated with erythrodermic pityriasis rubra pilaris. J Eur Acad Dermatol Venereol 2009; 23:217.</a></li><li><a class="nounderline abstract_t">Sahin MT, Oztürkcan S, Ermertcan AT, et al. Transient eruptive seborrhoeic keratoses associated with erythrodermic pityriasis rubra pilaris. Clin Exp Dermatol 2004; 29:554.</a></li><li><a class="nounderline abstract_t">Castanet J, Lacour JP, Perrin C, et al. Juvenile pityriasis rubra pilaris associated with hypogammaglobulinaemia and furunculosis. Br J Dermatol 1994; 131:717.</a></li><li><a class="nounderline abstract_t">Taniguchi S, Kawahira K, Kaneto K, Hamada T. Juvenile pityriasis rubra pilaris with isolated IgA deficiency. Eur J Pediatr 1997; 156:896.</a></li><li><a class="nounderline abstract_t">Shvili D, David M, Mimouni M. Childhood-onset pityriasis rubra pilaris with immunologic abnormalities. Pediatr Dermatol 1987; 4:21.</a></li><li><a class="nounderline abstract_t">Genovese G, Muratori S, Berti E, Marzano AV. Bullous erythroderma: novel association of pityriasis rubra pilaris with bullous pemphigoid. Clin Exp Dermatol 2019; 44:73.</a></li><li><a class="nounderline abstract_t">Randle HW, Winkelmann RK. Pityriasis rubra pilaris and celiac sprue with malabsorption. Cutis 1980; 25:626.</a></li><li><a class="nounderline abstract_t">Waldorf DS, Hambrick GW Jr. Vitamin A--responsive pityriasis rubra pilaris with myasthenia gravis. Arch Dermatol 1965; 92:424.</a></li><li><a class="nounderline abstract_t">Agharbi FZ, Elbekkal A, Baybay H, et al. [Association of pityriasis rubra pilaris and myasthenia]. Pan Afr Med J 2011; 10:7.</a></li><li><a class="nounderline abstract_t">Gül U, Gönül M, Kiliç A, et al. A case of pityriasis rubra pilaris associated with sacroileitis and autoimmune thyroiditis. J Eur Acad Dermatol Venereol 2008; 22:889.</a></li><li><a class="nounderline abstract_t">Tunnessen WW Jr, Nieburg PI, Voorhess ML. Hypothyroidism and pityriasis rubra pilaris. Response to thyroid hormone. J Pediatr 1976; 88:456.</a></li><li><a class="nounderline abstract_t">Orlandini V, Cogrel O, Doutre MS, et al. Pityriasis rubra pilaris and hypothyroidism. Efficacy of thyroid hormone replacement therapy in skin recovery. Br J Dermatol 2007; 156:606.</a></li><li><a class="nounderline abstract_t">Kelly A, Lally A. Pityriasis rubra pilaris: a rare inflammatory dermatosis. BMJ Case Rep 2018; 2018.</a></li><li><a class="nounderline abstract_t">Franzotti AM, Avelar JC, Cardoso TA, et al. Pityriasis Rubra Pilar and hypothyroidism. An Bras Dermatol 2014; 89:497.</a></li><li><a class="nounderline abstract_t">Holden CA, Curley RK. Down's syndrome and pityriasis rubra pilaris. Clin Exp Dermatol 1989; 14:332.</a></li><li><a class="nounderline abstract_t">Hazini AR, Rongioletti F, Rebora A. Pityriasis rubra pilaris and vitiligo in Down's syndrome. Clin Exp Dermatol 1988; 13:334.</a></li><li><a class="nounderline abstract_t">Terasaki K, Kanekura T, Saruwatari H, Kanzaki T. Classical juvenile pityriasis rubra pilaris in a patient with Down syndrome. Clin Exp Dermatol 2004; 29:49.</a></li><li><a class="nounderline abstract_t">Vitiello M, Miteva M, Romanelli P, et al. Pityriasis rubra pilaris: was it the first manifestation of colon cancer in a patient with pre-existing psoriasis? J Am Acad Dermatol 2013; 68:e43.</a></li><li><a class="nounderline abstract_t">Kloos C, Müller UA, Höffken K, et al. [Paraneoplastic pityriasis rubra pilaris in metastatic adenocarcinoma without diagnosable primary]. Dtsch Med Wochenschr 2002; 127:437.</a></li><li><a class="nounderline abstract_t">Garretson CB, Machan ML, Krejci-Manwaring J, et al. Letter: Adenocarcinoma of the lung associated with pityriasis rubra pilaris. Dermatol Online J 2011; 17:14.</a></li><li><a class="nounderline abstract_t">Kurzydlo AM, Gillespie R. Paraneoplastic pityriasis rubra pilaris in association with bronchogenic carcinoma. Australas J Dermatol 2004; 45:130.</a></li><li><a class="nounderline abstract_t">Bar-Ilan E, Gat A, Sprecher E, Zeeli T. Paraneoplastic pityriasis rubra pilaris: case report and literature review. Clin Exp Dermatol 2017; 42:54.</a></li><li><a class="nounderline abstract_t">Sharma S, Weiss GR, Paulger B. Pityriasis rubra pilaris as an initial presentation of hepatocellular carcinoma. Dermatology 1997; 194:166.</a></li><li><a class="nounderline abstract_t">Reinhardt LA, Rosen T. Pityriasis rubra pilaris as the initial manifestation of leukemia. Cutis 1983; 31:100.</a></li><li><a class="nounderline abstract_t">Quenan S, Kaya G, Laffitte E. Pityriasis rubra pilaris and transitional meningioma: a fortuitous association? Eur J Dermatol 2015; 25:273.</a></li><li><a class="nounderline abstract_t">Bell SL, Patel AN, Leach IH, Cohen SN. Consider triggers for pityriasis rubra pilaris. Clin Exp Dermatol 2014; 39:403.</a></li><li><a class="nounderline abstract_t">Tannenbaum CB, Billick RC, Srolovitz H. Multiple cutaneous malignancies in a patient with pityriasis rubra pilaris and focal acantholytic dyskeratosis. J Am Acad Dermatol 1996; 35:781.</a></li><li><a class="nounderline abstract_t">Kwak RB, Hafeez F, Lian C, Nambudiri VE. Paraneoplastic pityriasis rubra pilaris heralding onset of new hematologic malignancy. Am J Hematol 2021; 96:272.</a></li><li><a class="nounderline abstract_t">Batchelor RJ, Yung A, Merchant W, Goodfield MJ. Pityriasis rubra pilaris as the initial presentation of renal cell carcinoma? Clin Exp Dermatol 2005; 30:442.</a></li><li><a class="nounderline abstract_t">Remedios IM, Jensen JD, Beckum K, et al. Paraneoplastic pityriasis rubra pilaris as the presenting manifestation of metastatic squamous cell carcinoma. J Drugs Dermatol 2014; 13:610.</a></li><li><a class="nounderline abstract_t">Batinac T, Kujundzić M, Peternel S, et al. Pityriasis rubra pilaris in association with laryngeal carcinoma. Clin Exp Dermatol 2009; 34:e917.</a></li><li><a class="nounderline abstract_t">Errichetti E, Piccirillo A, Stinco G. Dermoscopy as an auxiliary tool in the differentiation of the main types of erythroderma due to dermatological disorders. Int J Dermatol 2016; 55:e616.</a></li><li><a class="nounderline abstract_t">Errichetti E, Stinco G. Dermatoscopy in life-threatening and severe acute rashes. Clin Dermatol 2020; 38:113.</a></li><li><a class="nounderline abstract_t">Sławińska M, Sokołowska-Wojdyło M, Sobjanek M, et al. The significance of dermoscopy and trichoscopy in differentiation of erythroderma due to various dermatological disorders. J Eur Acad Dermatol Venereol 2021; 35:230.</a></li><li><a class="nounderline abstract_t">Jha AK, Lallas A, Sonthalia S, et al. Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy. Dermatol Pract Concept 2018; 8:299.</a></li><li><a class="nounderline abstract_t">López-Gómez A, Vera-Casaño Á, Gómez-Moyano E, et al. Dermoscopy of circumscribed juvenile pityriasis rubra pilaris. J Am Acad Dermatol 2015; 72:S58.</a></li><li><a class="nounderline abstract_t">Nair PA, Sheth N. Dermoscopy of Juvenile Circumscribed Pityriasis Rubra Pilaris. Indian Dermatol Online J 2018; 9:474.</a></li><li><a class="nounderline abstract_t">Lallas A, Apalla Z, Karteridou A, Lefaki I. Photoletter to the editor: Dermoscopy for discriminating between pityriasis rubra pilaris and psoriasis. J Dermatol Case Rep 2013; 7:20.</a></li><li><a class="nounderline abstract_t">Abdel-Azim NE, Ismail SA, Fathy E. Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy. Arch Dermatol Res 2017; 309:311.</a></li><li><a class="nounderline abstract_t">Westfried M, Rosenthal JC, Coppola A, Rapp Y. Sézary syndrome presenting as a follicular dermatosis. Cutis 1982; 29:390.</a></li><li><a class="nounderline abstract_t">Gloor AD, van Rhyn M, Schlapbach C. Erythema gyratum repens-like eruption after anti-IL-17 therapy of pityriasis rubra pilaris. J Eur Acad Dermatol Venereol 2021; 35:e38.</a></li><li><a class="nounderline abstract_t">Almaani N, Robson A, Sarkany R, Griffiths WA. Erythema gyratum repens associated with pityriasis rubra pilaris. Clin Exp Dermatol 2011; 36:161.</a></li><li><a class="nounderline abstract_t">Richey PM, Fairley JA, Stone MS. Transformation from pityriasis rubra pilaris to erythema gyratum repens-like eruption without associated malignancy: A report of 2 cases. JAAD Case Rep 2018; 4:944.</a></li><li><a class="nounderline abstract_t">Davenport R, Le ST, Gin A, et al. Resolving classic pityriasis rubra pilaris, mimicker of erythema gyratum repens. Australas J Dermatol 2018; 59:232.</a></li><li><a class="nounderline abstract_t">Marchetti MA, Greer KE. Pityriasis rubra pilaris treated with methotrexate resolving with an erythema gyratum repens-like appearance. J Am Acad Dermatol 2013; 69:e32.</a></li><li><a class="nounderline abstract_t">Cheesbrough MJ, Williamson DM. Erythema gyratum repens, a stage in the resolution of pityriasis rubra pilaris? Clin Exp Dermatol 1985; 10:466.</a></li><li><a class="nounderline abstract_t">Gebauer K, Singh G. Resolving pityriasis rubra pilaris resembling erythema gyratum repens. Arch Dermatol 1993; 129:917.</a></li><li><a class="nounderline abstract_t">Darling MJ, Lambiase MC, Young RJ. Tinea versicolor mimicking pityriasis rubra pilaris. Cutis 2005; 75:265.</a></li><li><a class="nounderline abstract_t">Berry M, Khachemoune A. Extensive tinea versicolor mimicking Pityriasis rubra pilaris. J Drugs Dermatol 2009; 8:490.</a></li><li><a class="nounderline abstract_t">Surjana D, Robertson I, Kennedy G, et al. Acute cutaneous graft-versus-host disease resembling type II (atypical adult) pityriasis rubra pilaris. Australas J Dermatol 2015; 56:e21.</a></li><li><a class="nounderline abstract_t">Wang JY, Tabata MM, Pugliese S, et al. Pityriasis rubra pilaris-like graft-vs-host disease following allogeneic stem cell transplant in two patients. Clin Case Rep 2019; 7:2491.</a></li></ol></div><div id="topicVersionRevision">Topic 15283 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Tarral C. Observation CXVIII. In: Traité Théorique et Pratique des Maladies de la Peau, 2nd ed, Rayer P (Ed), Bailliere, 1835. p.158.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pityriasis pilaris, maladie de peau non decrite par les dermatologists</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Du pityriasis rubra pilaire</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18819727" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Juvenile pityriasis rubra pilaris: report of 28 cases in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12196748" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pityriasis rubra pilaris in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8050142" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pityriasis rubra pilaris: a new proposed classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15419810" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pityriasis rubra pilaris; a clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7398119" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26963004" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Epidemiologic, Clinicopathologic, Diagnostic, and Management Challenges of Pityriasis Rubra Pilaris: A Case Series of 100 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33771592" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical features and eosinophilia in pityriasis rubra pilaris: A multicenter cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24783259" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pityriasis rubra pilaris: clinicopathological study of 32 cases from Lebanon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3562357" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pityriasis rubra pilaris in childhood: a long-term study of 29 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1934568" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pityriasis rubra pilaris in Singapore.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10494736" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pityriasis rubra pilaris: a retrospective analysis of 43 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30520557" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Systemic therapies of pityriasis rubra pilaris: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5797957" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Pityriasis rubra pilaris. A follow-up study of 57 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4235165" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Skin diseases in Kenya. A clinical and histopathological study of 3,168 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2611132" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pityriasis rubra pilaris in Indians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/939336" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pityriasis rubra pilaris. A clinico-pathological study with a special reference to autoradiography and histocompatibility antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22703878" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Familial pityriasis rubra pilaris is caused by mutations in CARD14.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25734815" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Analysis of CARD14 Polymorphisms in Pityriasis Rubra Pilaris: Activation of NF-κB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26203641" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29980436" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Gain-of-Function Mutation of Card14 Leads to Spontaneous Psoriasis-like Skin Inflammation through Enhanced Keratinocyte Response to IL-17A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29689250" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : CARD14 Gain-of-Function Mutation Alone Is Sufficient to Drive IL-23/IL-17-Mediated Psoriasiform Skin Inflammation In Vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24359224" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Increased epidermal expression and absence of mutations in CARD14 in a series of patients with sporadic pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34246621" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Pityriasis Rubra Pilaris Response to IL-17A Inhibition Is Associated with IL-17C and CCL20 Protein Levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36167251" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pityriasis Rubra Pilaris Transcriptomics Implicate T Helper 17 Signaling and Correlate with Response to Ixekizumab, with Distinct Gene Expression Profiles in Nonresponders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35701384" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34491907" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32687965" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Drugs associated with development of pityriasis rubra pilaris: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5775066" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Systemic lupus erythematosus: a report of forty-five cases with unusual clinical and immunological features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8547057" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pityriasis rubra pilaris and human immunodeficiency virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10354168" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pityriasis rubra pilaris in black South Africans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33937496" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pityriasis rubra pilaris in skin of color.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35895853" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1269179" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pityriasis rubra pilaris--an historical approach. 2. Clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5783082" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pityriasis rubra pilaris. Report of a case and analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32965475" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Characterizing Disease Features and Other Medical Diagnoses in Patients With Pityriasis Rubra Pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The comprehensive impact of pityriasis rubra pilaris on physical symptoms, mental health, and activities of daily living: A mixed methods study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16309476" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Photosensitive pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16149942" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Photoaggravated pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10233350" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Bath-PUVA as a treatment for Pityriasis rubra pilaris provoked by ultraviolet B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7949494" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pityriasis rubra pilaris exacerbated by ultraviolet B phototherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534654" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Narrow-band UVB-associated lesional blisters in pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27512362" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Photosensitive pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8180100" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Photosensitive and phototriggered pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30710600" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Pityriasis rubra pilaris: A study evaluating patient quality of life in 2 populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19034146" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Bilateral herpes simplex keratitis with unilateral secondary bacterial keratitis and corneal perforation in a patient with pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17401317" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Peripheral ulcerative keratitis in pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3782535" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The nails in adult type 1 pityriasis rubra pilaris. A comparison with Sézary syndrome and psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1869640" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pityriasis rubra pilaris and HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8555047" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Pityriasis rubra pilaris and HIV infection: a part of the spectrum of HIV-associated follicular syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8335758" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pityriasis rubra pilaris, acne conglobata, and elongated follicular spines: an HIV-associated follicular syndrome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29477734" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : CARD14-associated papulosquamous eruption: A spectrum including features of psoriasis and pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31849081" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Histopathologic findings characteristic of CARD14-associated papulosquamous eruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1430369" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Kaposi's varicelliform eruption in a patient with pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21732959" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A case of pityriasis rubra pilaris with associated focal acantholytic dyskeratosis complicated by Kaposi's varicelliform eruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23432393" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Kaposi's varicelliform eruption in a patient with pityriasis rubra pilaris (pityriasis rubra pilaris herpeticum).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23432393" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Kaposi's varicelliform eruption in a patient with pityriasis rubra pilaris (pityriasis rubra pilaris herpeticum).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3766917" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Histologic criteria for the diagnosis of pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9274959" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The clinical and histomorphological features of pityriasis rubra pilaris. A comparative analysis with psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26381023" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The Incidence of Acantholysis in Pityriasis Rubra Pilaris-Histopathological Study Using Multiple-Step Sections and Clinicopathologic Correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22097993" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pityriasis rubra pilaris: the clinical context of acantholysis and other histologic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30045068" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pityriasis Rubra Pilaris With Extensive Follicular Acantholysis Resembling Pemphigus Vulgaris: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19602067" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : PRP with subcorneal acantholysis: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8763450" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Arthropathic pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10513817" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : The relationship between pityriasis rubra pilaris and inflammatory arthritis: case report and response of the arthritis to anti-tumor necrosis factor immunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11860571" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Atypical pityriasis rubra pilaris associated with arthropathy and osteoporosis: a case report with 15-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12399682" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pityriasis rubra pilaris in association with polyarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15154613" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A review of pityriasis rubra pilaris and rheumatologic associations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22766575" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Arthritis associated with pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4127046" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Pityriasis rubra pilaris with muscle and joint involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3499787" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Acro-osteolysis secondary to pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9292098" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pityriasis rubra pilaris and a seronegative polyarthritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2461032" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Eruptive seborrheic keratoses associated with erythrodermic pityriasis rubra pilaris. Possible role of retinoid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18482315" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Eruptive seborrhoeic keratoses associated with erythrodermic pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15347352" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Transient eruptive seborrhoeic keratoses associated with erythrodermic pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7999608" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Juvenile pityriasis rubra pilaris associated with hypogammaglobulinaemia and furunculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9392412" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Juvenile pityriasis rubra pilaris with isolated IgA deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2954034" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Childhood-onset pityriasis rubra pilaris with immunologic abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30129048" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Bullous erythroderma: novel association of pityriasis rubra pilaris with bullous pemphigoid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7379593" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Pityriasis rubra pilaris and celiac sprue with malabsorption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5835336" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Vitamin A--responsive pityriasis rubra pilaris with myasthenia gravis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22187589" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : [Association of pityriasis rubra pilaris and myasthenia].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18031492" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A case of pityriasis rubra pilaris associated with sacroileitis and autoimmune thyroiditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1245956" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Hypothyroidism and pityriasis rubra pilaris. Response to thyroid hormone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17300270" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Pityriasis rubra pilaris and hypothyroidism. Efficacy of thyroid hormone replacement therapy in skin recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29440245" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Pityriasis rubra pilaris: a rare inflammatory dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24937828" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pityriasis Rubra Pilar and hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2531644" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Down's syndrome and pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2978467" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Pityriasis rubra pilaris and vitiligo in Down's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14723722" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Classical juvenile pityriasis rubra pilaris in a patient with Down syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23317984" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Pityriasis rubra pilaris: was it the first manifestation of colon cancer in a patient with pre-existing psoriasis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11870558" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : [Paraneoplastic pityriasis rubra pilaris in metastatic adenocarcinoma without diagnosable primary].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22136870" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Letter: Adenocarcinoma of the lung associated with pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15068463" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Paraneoplastic pityriasis rubra pilaris in association with bronchogenic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27896859" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Paraneoplastic pityriasis rubra pilaris: case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9094467" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Pityriasis rubra pilaris as an initial presentation of hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6825457" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Pityriasis rubra pilaris as the initial manifestation of leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25906197" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Pityriasis rubra pilaris and transitional meningioma: a fortuitous association?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24635086" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Consider triggers for pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8912581" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Multiple cutaneous malignancies in a patient with pityriasis rubra pilaris and focal acantholytic dyskeratosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32501564" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Paraneoplastic pityriasis rubra pilaris heralding onset of new hematologic malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15953096" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Pityriasis rubra pilaris as the initial presentation of renal cell carcinoma?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24809888" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Paraneoplastic pityriasis rubra pilaris as the presenting manifestation of metastatic squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20055867" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Pityriasis rubra pilaris in association with laryngeal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27420287" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Dermoscopy as an auxiliary tool in the differentiation of the main types of erythroderma due to dermatological disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32197741" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Dermatoscopy in life-threatening and severe acute rashes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33073390" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The significance of dermoscopy and trichoscopy in differentiation of erythroderma due to various dermatological disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30479860" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25500045" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Dermoscopy of circumscribed juvenile pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30505800" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Dermoscopy of Juvenile Circumscribed Pityriasis Rubra Pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23580911" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Photoletter to the editor: Dermoscopy for discriminating between pityriasis rubra pilaris and psoriasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28280914" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7083914" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Sézary syndrome presenting as a follicular dermatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32580240" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Erythema gyratum repens-like eruption after anti-IL-17 therapy of pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20637029" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Erythema gyratum repens associated with pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30345340" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Transformation from pityriasis rubra pilaris to erythema gyratum repens-like eruption without associated malignancy: A report of 2 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29192964" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Resolving classic pityriasis rubra pilaris, mimicker of erythema gyratum repens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23768305" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Pityriasis rubra pilaris treated with methotrexate resolving with an erythema gyratum repens-like appearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4075579" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Erythema gyratum repens, a stage in the resolution of pityriasis rubra pilaris?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8323326" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Resolving pityriasis rubra pilaris resembling erythema gyratum repens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15984626" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Tinea versicolor mimicking pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19537374" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Extensive tinea versicolor mimicking Pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25688705" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Acute cutaneous graft-versus-host disease resembling type II (atypical adult) pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31893086" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Pityriasis rubra pilaris-like graft-vs-host disease following allogeneic stem cell transplant in two patients.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
